Reforms in China Affect IVD Companies’ Q3 2025 Earnings

By Mark Terry | From the Volume XXXII, Number 16 – November 17, 2025 Issue

Most of the in vitro diagnostics (IVD) manufacturers that serve clinical laboratories worldwide reported facing financial “headwinds” in the China IVD market that affected their third-quarter performance. This was due to policy changes in the country…

Read More

---

What Private Equity Sees in Diagnostics

By Scott Wallask | From the Volume XXXII, Number 16 – November 17, 2025 Issue

CEO SUMMARY: Hologic’s acquisition by private equity firms Blackstone and TPG marks one of the year’s largest in vitro diagnostics transactions and a clear vote of confidence in the sector’s resilience. Industry analyst Bruce Carlson unpacks what the buyout …

Read More

---

October 27, 2025, Intelligence: Late-Breaking Lab News

By Robert Michel | From the Volume XXXII, No. 15 – October 27, 2025 Issue

In yet another shuffling of the in vitro diagnostics (IVD) space, Hologic announced on Oct. 21 that it was being acquired by private equity firms Blackstone and TPG for $18.3 billion. The deal will take Hologic off the Nasdaq, likely in early 2026. TPG and Blackstone lauded Hol…

Read More

---

2025 Ranking of the World’s Top 13 IVD Corporations

By Mark Terry | From the Volume XXXII, No. 13 – September 15, 2025 Issue

BASED ON PUBLICLY-REPORTED 2024 DIAGNOSTICS-RELATED REVENUE, four in vitro diagnostics (IVD) companies continue to dominate the global market, as they have for the last two years: Thermo Fisher Scientific, Roche, Danaher, and Abbott Laboratories. The top 13 companies …

Read More

---

Despite Trade Tariffs, IVD Firms Report Upbeat Earnings

By Mark Terry | From the Volume XXXII, No. 12 – August 25, 2025 Issue

LEADING IN VITRO DIAGNOSTICS (IVD) COMPANIES RECENTLY REPORTED POSITIVE QUARTERLY FINANCIALS despite swirling concerns about trade tariffs and cuts to US federal research grants. It’s not yet clear what the long-term effect of tariffs’ will be on IVD manu…

Read More

---

June 23, 2025, Intelligence: Late-Breaking Lab News

By Scott Wallask | From the Volume XXXII, No. 9 – June 23, 2025 Issue

Clinical labs that have business in clinical trials involving genetic samples should note that on June 18, the Food and Drug Administration (FDA) ordered a review of new trials that send samples to “hostile countries for genetic engineering.” The FDA mentioned China specifically. Th…

Read More

---

Global IVD Companies Issue Fourth Quarter 2024 Earnings

By Robert Michel | From the Volume XXXII, No. 5 – March 31, 2025 Issue

OVERALL, IN VITRO DIAGNOSTICS (IVD) COMPANIES REPORTED A MIXED BAG of financial results for the quarter ending Dec. 31, 2024, with Becton, Dickinson and Company, Abbott Laboratories, and Siemens Healthineers showing the most momentum based on r…

Read More

---

Global IVD Companies Issue Third Quarter 2024 Earnings

By Robert Michel | From the Volume XXXI, No. 16 – November 25, 2024 Issue

HERE IS A SUMMARY OF THE THIRD QUARTER FINANCIAL PERFORMANCE of t…

Read More

---

Global IVD Companies Report Second Quarter 2024 Earnings

By Robert Michel | From the Volume XXXI, No. 13 – September 23, 2024 Issue

IN THE SECOND QUARTER OF 2024, in vitro diagnostics (IVD) companies reported solid revenues as well as new tests, analyzers, and automation. Most of the IVD companies boosted diagnostic sales in low single digit amounts. During the earnings calls, financial analysts asked company leade…

Read More

---

2023 Ranking of the World’s Top 13 IVD Corporations

By Robert Michel | From the Volume XXXI, No. 10 – July 22, 2024 Issue

BASED ON 2023 DIAGNOSTICS-RELATED REVENUE, four in vitro diagnostics (IVD) manufacturers continued to lead the global IVD market just as they did in 2022. They are: Thermo Fisher Scientific, Inc., Roche Holdings, Abbott Laboratories, and Danaher Corporation. Th…

Read More

---